What is the new age range approved for GSK's Arexvy vaccine?

The U.S. Food and Drug Administration has expanded the approved age range for GSK's Arexvy vaccine to include adults aged 18 to 49.

Who is eligible for the expanded Arexvy vaccine approval?

Adults aged 18 to 49 who are at increased risk of lower respiratory tract disease caused by respiratory syncytial virus (RSV) are now eligible.

What does the FDA's expansion mean for the Arexvy vaccine?

The FDA's expansion means GSK's Arexvy vaccine can now be used to protect a wider group of at-risk adults from RSV and its associated respiratory illnesses.

Home / Health / FDA Approves GSK RSV Vaccine for Younger Adults

FDA Approves GSK RSV Vaccine for Younger Adults

13 Mar

•

Summary

GSK's Arexvy vaccine now approved for adults aged 18-49.
New approval targets those at increased risk of RSV.
FDA expanded the age range for the respiratory vaccine.

FDA Approves GSK RSV Vaccine for Younger Adults

The U.S. Food and Drug Administration has broadened the approved age demographic for GSK's Arexvy vaccine. This significant expansion now includes adults between the ages of 18 and 49.

This new eligibility specifically targets individuals identified as being at an increased risk of developing lower respiratory tract disease. This condition is caused by the respiratory syncytial virus (RSV).

This regulatory decision by the FDA enhances the availability of the RSV vaccine. It ensures that a wider group of at-risk adults can now access protection against the potentially serious respiratory illness.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.